These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 17265022)

  • 21. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P; Caliliw R; Belldegrun A; Bonavida B
    Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.
    Li Z; Peng H; Xu Q; Ye Z
    J Orthop Res; 2012 May; 30(5):824-30. PubMed ID: 22025284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
    Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
    AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.
    Wada I; Matsushita H; Noji S; Mori K; Yamashita H; Nomura S; Shimizu N; Seto Y; Kakimi K
    Cancer Med; 2014 Apr; 3(2):362-75. PubMed ID: 24515916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
    D'Asaro M; La Mendola C; Di Liberto D; Orlando V; Todaro M; Spina M; Guggino G; Meraviglia S; Caccamo N; Messina A; Salerno A; Di Raimondo F; Vigneri P; Stassi G; Fourniè JJ; Dieli F
    J Immunol; 2010 Mar; 184(6):3260-8. PubMed ID: 20154204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
    Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
    J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
    Poonia B; Pauza CD
    Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human Vγ9Vδ2 T cells show potent antitumor activity against zoledronate-sensitized OSCC cell lines.
    Domae E; Hirai Y; Ikeo T; Goda S; Tsuji K
    J BUON; 2018 Dec; 23(7):132-138. PubMed ID: 30722122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.
    Sugai S; Yoshikawa T; Iwama T; Tsuchiya N; Ueda N; Fujinami N; Shimomura M; Zhang R; Kaneko S; Uemura Y; Nakatsura T
    Int J Oncol; 2016 May; 48(5):1794-804. PubMed ID: 26936487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
    Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
    J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct tumour specificity and IL-7 requirements of CD56(-)and CD56(+) subsets of human gamma delta T cells.
    Zheng B; Lam C; Im S; Huang J; Luk W; Lau SY; Yau KK; Wong C; Yao K; Ng MH
    Scand J Immunol; 2001 Jan; 53(1):40-8. PubMed ID: 11169205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.
    Coscia M; Vitale C; Peola S; Foglietta M; Rigoni M; Griggio V; Castella B; Angelini D; Chiaretti S; Riganti C; Guarini A; Drandi D; Ladetto M; Bosia A; Foà R; Battistini L; Boccadoro M; Fournié JJ; Massaia M
    Blood; 2012 Oct; 120(16):3271-9. PubMed ID: 22932792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
    Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
    Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
    Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
    J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
    J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expansion of human peripheral blood γδ T cells using zoledronate.
    Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired function of gamma-delta lymphocytes in melanoma patients.
    Petrini I; Pacini S; Galimberti S; Taddei MR; Romanini A; Petrini M
    Eur J Clin Invest; 2011 Nov; 41(11):1186-94. PubMed ID: 22775565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
    Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
    Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
    Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
    Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.